Clinical status and treatments before extracorporeal membrane oxygenation (ECMO) in the Glenfield and UK ECMO trial cohorts
| Glenfield (n = 145) | UK ECMO trial (n = 63) | p Value | |
|---|---|---|---|
| Values in parentheses are percentages. | |||
| iNO, Inhaled nitric oxide; HFOV, high frequency oscillatory ventilation. | |||
| Oxygenation index | |||
| ⩽40 | 42 (29) | – | |
| >40 | 103 (71) | ||
| Mean oxygenation index | 51 | 63 | 0.05 |
| Age at ECMO | |||
| <24 h | 70 (48) | 23 (37) | NS |
| 24–48 h | 44 (31) | 23 (37) | NS |
| >48 h | 31 (21) | 17 (26) | NS |
| Therapies before ECMO | |||
| Pulmonary vasodilators excluding iNO | 57 (39) | 54 (86) | <0.01 |
| iNO | 65 (45) | 5 (8) | <0.01 |
| Inotrope | 110 (75) | 50 (79) | NS |
| HFOV | 77 (53) | 4 (6) | <0.01 |
| Muscle relaxant | 121(83) | 54 (86) | NS |
| Surfactant | 116 (80) | 16 (25) | <0.01 |